Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting
Launched by KOREA UNIVERSITY ANAM HOSPITAL · Jun 30, 2015
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Provision of informed consent prior to any study specific procedures
- • 2. Newly diagnosed type 2 diabetic patients or type 2 diabetic patients on hypoglycemic agents between the age of 30 to 70
- • 3. Non-ST elevation Acute coronary syndrome with successful coronary stent implantation (with TIMI flow grade 3 after the procedure)
- Exclusion Criteria:
- • 1. Hypersensitivity to ticagrelor, prasugrel or any of the excipients
- • 2. No prior use of either ticagrelor or prasugrel within a month prior to randomization.
- • 3. History of intracranial bleeding at any time
- • 4. Active pathologic bleeding
- • 5. Hemoglobin A1c \>9%
- • 6. Type 1 diabetes
- • 7. Decreased serum platelet level (\< 100,000/uL)
- • 8. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin
- • 9. Gastrointestinal bleed within the past 6 months, or major surgery within 30 days
- • 10. Renal failure requiring dialysis or anticipated need for dialysis during the course of the study
- • 11. Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study
- • 12. Involvement in the planning and/or conduct of the study
- • 13. Left ventricular ejection fraction \< 40%
- • 14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase \> twice the upper limit)
- • 15. Gastrointestinal disorder such as Crohn's disease
- • 16. Alcohol abuse
- • 17. Steroid or hormone replacement therapy
- • 18. Serum creatinine \> 2.0 mg/dL.
- • 19. Prior history of CVA or stroke
- • 20. Body weight \< 60 kg
- • 21. Life expectancy less than a year
- • 22. Known pregnancy, breast-feeding, or intend to become pregnant during the study period
About Korea University Anam Hospital
Korea University Anam Hospital is a leading academic medical institution in South Korea renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies that aim to improve patient outcomes and contribute to medical knowledge. With a strong emphasis on ethical practices and patient safety, Korea University Anam Hospital collaborates with various stakeholders to facilitate cutting-edge research across diverse therapeutic areas, fostering an environment that promotes scientific discovery and translational medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials